FDA approves Shire's Vyvanse for ADHD

02/24/2007 | MSNBC

Shire PLC says the amphetamine-based drug is meant to supplant its top-selling Adderall XR when that drug goes off patent in 2009. Shire says it believes a new formulation, which makes the drug inactive unless swallowed, will curtail potential abuse of the drug.

View Full Article in:

MSNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX